Quick Answer
Damora Therapeutics, Inc. reported Total Assets of $260.53 million for fiscal year 2025.
Damora Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $260.53M | +1420.7% |
| 2024 | $17.13M | -55.2% |
| 2023 | $38.23M | -47.8% |
| 2022 | $73.19M | -40.1% |
| 2021 | $122.22M | -28.8% |
| 2020 | $171.60M | +203.1% |
| 2019 | $56.61M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.74M | -54.1% | -21.6% |
| June 30, 2025 | $13.69M | -49.8% | -10.9% |
| March 31, 2025 | $15.37M | -52.7% | -10.3% |
| December 31, 2024 | $17.13M | -55.2% | -26.7% |
| September 30, 2024 | $23.38M | -53.3% | -14.4% |
| June 30, 2024 | $27.30M | -53.6% | -15.9% |
| March 31, 2024 | $32.48M | -49.7% | -15.0% |
| December 31, 2023 | $38.23M | -47.8% | -23.6% |
- Damora Therapeutics, Inc. showed an increase of +1420.7% in Total Assets compared to the prior fiscal year.
- Over the 2019–2025 period, Damora Therapeutics, Inc.’s total assets has grown by 360.2% (from $56.61 million to $260.53 million).
- The most recent figure is from Damora Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: